

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

17beta-oestradiol-induced gene expression in cattle prostate: biomarkers to detect illegal use of growth promoters

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/51843> since

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:

Questa è la versione dell'autore dell'opera:

[Vet Rec.](#) 2009 Apr 11;164(15):459-64.]

The definitive version is available at:

La versione definitiva è disponibile alla URL:

[<http://veterinaryrecord.bmj.com/content/164/15/459.long>]

17p-estradiol-induced gene expression in prostate cell culture and tissue from cattle: biomarkers to detect illegal use of growth promoters

R. De Maria, S. Divari, M. Gorla, E. Bollo, F. T. Cannizzo, M. Olivero, G. Barbarino, B. Biolatti

The effects of 17p-oestradiol (E_2) on gene expression in cultures of bovine primary prostate stromal cells (BPSCs) and prostate gland tissue were studied. In the first part of the study, BPSCs were grown in the presence of E_2 from the first passage to the end of the experiment; a second group was treated in the same way but the treatment was suspended for 48 hours before the end of the experiment; a third group of BPSCs served as a control. In the second part of the study, five male veal calves, aged 130 days, were treated four times intramuscularly with 10 mg of E_2 at intervals of two weeks and then euthanased two weeks after the last treatment. Quantitative **PCR** and immunohistochemistry were used to evaluate the expression of fibroblast growth factor (**FGF**) receptors (FGFRs), FGFs, progesterone receptor, androgen receptor and oestrogen receptor in BPSCs and prostate tissue. E_2 induced a significant over-expression of progesterone receptor in both BPSCs and prostate tissue. There was also a marked up-regulation of **FGFR** types 1, 2 and 3 genes observed in the BPSCs.

Veterinary Record (2009) **164**, 000-000

R. De Maria, BSc, **S. Divari**, BSc,

E. Bollo, DVM,

F. T. Cannizzo, BSc,

B. Biolatti, DVM,

Department of Animal Pathology,

University of Turin, School of

Veterinary Medicine, Grugliasco

(Turin), Italy

M. Gorla, BSc,

Institute of Zooprophyllaxis of

Piemonte, Liguria and Valle d'Aosta

(Turin), Italy

M. Olivero, BSc,

Laboratory of Cancer Genetics of the

Institute for Cancer Research and

Treatment (IRCC), University of

Turin School of Medicine, Candiolo

(Turin), Italy

G. Barbarino, DVM,

Regione Piemonte Settore, Sanita

Animale ed Igiene degli Allevamenti,

C. So Stati Uniti, 1 Turin, Segretaria,

Italy

E-mail for correspondence: raffaella.demaria@unito.it

THE illegal use of growth-promoting agents is a significant problem in animal production. In this context, sex steroids, β -agonists, thyrostatics and corticosteroids are often administered to cattle. Anabolic steroids increase growth rate, stimulate the growth of muscle and reduce fat tissue in calves (Groot and others 1998) by acting on lipid and protein metabolism. The use of natural and synthetic hormones as growth promoters in food producing animals is prohibited in the European Union and analytical methods are employed to prevent their illegal use (Anon 1996, Courtheyn and others 2002). However, these techniques appear to give unsatisfactory results (Groot and others 2007) and it is therefore essential to develop indirect biomarkers to reinforce veterinary controls.

In recent years, increasing attention has been paid to the study of the effects of growth promoters on target organs, most of all on the histo-pathology of the accessory sex glands (Groot and others 2007). Among the anabolic steroids, 17β -oestradiol (E_2) is one of the most efficient. Histologically, it induces hyperplasia and metaplasia of prostate cells and the urethral epithelium (Ruitenbergh and others 1970, Kroes and others 1971, Groot and others 1998). Squamous cell metaplasia is a specific response to a variety of oestrogenic substances, including E_2 , diethylstilbestrol and zeranol, and it is considered to be a reliable histological marker to assess their oestrogenic action in cattle (Biolatti and others 2003). However, more accurate and specific methods are required to reinforce the methods described above; for this purpose the development of genomic methods could lead to a potentially reliable technique, easily transferable to veterinary public health.

Oestrogens and androgens regulate the growth and differentiation of the prostate gland in rats (Naslund and Coffey 1986) and mice (Gail and others 2001). In human beings, the homeostasis of normal prostate depends on a two-way communication between epithelial and stromal compartments, including smooth muscle cells, myofibroblasts, fibroblasts and blood vessel cells (International Prostate Health Council 2000). Stromal cells regulate the growth and function of the prostate, acting as epithelial inducers and participating in a close paracrine stromal-epithelial regulatory network in the adult gland (Franks and others 1970, Cunha and others 1980, 2004a). They have receptors for androgens, oestrogens, glucocorticoids and progesterone (Naslund and Coffey 1986). Oestrogens act through their specific receptors, oestrogen receptor xx, (ERxx) and oestrogen receptors (ERs) α and β (Kuiper and others 1996, Leav and others 2001), expressed in the prostatic stroma and epithelium, respectively. As a result of their interactions with oestrogens, stromal cells synthesise various growth factors: epidermal growth factor, keratinocyte growth factor, insulin-like growth factors I and II, fibroblast growth factors (FGFs) and transforming growth factors α and β (Wong and Tarn 2002, Bektic and others 2004). These substances mediate many functions, including cellular secretion, proliferation, differentiation and apoptosis (Steiner 1993). Among several growth factors and receptors implicated in the proliferation of the prostate, the family of FGFs and FGF receptors (FGFRs) plays a critical role (Kwabi-Addo and others 2004, Gowardhan and others 2005). The gene encoding for progesterone receptor (PR) is regulated by oestrogens and shows the typical oestrogen receptor element at the 5' end. This gene is widely accepted as a marker of oestrogenic action in different human and murine tissues (Graham and Clarke 1997, Kurita and others 2000, Williams and others 2000). The PR gene and its protein have been characterised in the reproductive system of female cattle where they behave and have a tissue distribution similar to that in women (Schams and others 2003, Taylor and others 2006), but there is no evidence of their presence in the reproductive system of male cattle.

The aim of this work was to study E_2 -related gene expression, first by challenging cultures of bovine primary prostate stromal cells (BPSCs) to better understand the biological role of E_2 in prostate cell physiology, and secondly, in veal calves, to establish potential new biomarkers to be applied in the detection of calves treated illegally with hormones.

Materials and methods

Establishment of bovine prostate stromal cell cultures and experimental design

Samples of prostate tissue were obtained postmortem from six-month-old Holstein calves. The tissue was dissected under sterile conditions and the samples were minced into small pieces and spread on to the surface of 25 cm² culture flasks according to the methods described by Zhang and others (1997). The arising cells were routinely maintained in MCDB-131 medium (Sigma) supplemented with 15 per cent decalcified horse serum (Gibco), non-essential amino acids (Sigma), 5 μ g/ml insulin (Sigma), 10 mg/ml transferrin (Sigma), 5 ng/ml sodium selenite (Sigma), 100nM dexamethasone (Sigma), 0-1 ng/ml epidermal growth factor (Gibco), 1 ng/ml basic FGF (bFGF) (Gibco), an antibiotic-antimycotic cocktail (Sigma) and glutamine (Sigma). After seven days, the medium was removed and then renewed every three days. When the primary culture reached two-thirds confluence, the cells were detached with 3 ml trypsin/EDTA solution and poured through a 100 μ m mesh to remove pieces of tissue. The cells were used for the experiment at the fifth passage, when a higher density of BPSCs were available. The confluent cells were subdivided as follows: group C (control), cells grown in MCDB-131 medium with supplements and without phenol red and E_2 ; group T (treated), cells cultured in MCDB-131 medium with 100nM E_2 for five passages; group S (suspended), cells cultured in 100nM E_2 for five passages and then grown without E_2 for 48 hours. All the experiments were conducted in triplicate.

Two groups of 130-day-old male Holstein veal calves weighing an average 178 kg were used. They were fed liquid milk replacer twice a day and after a month 0.5 kg/day of straw was added to their diet according to the recommendations of the European Commission (97/182/EC). The five calves in group T were injected intramuscularly with 10 mg E_2 on four occasions at intervals of 15 days, an anabolic dosage according to Vanderwal and others (1975) and Meyer Heinrich (2001). They were slaughtered 15 days after the last injection. The three calves in group C served as controls. Samples of prostate tissue from the treated and control calves were fixed in 10 per cent buffered formalin solution for histological examination and in RNA/later (Ambion) for molecular studies.

Authorisation to carry out the experiment was given by the Italian Ministry of Health and the Bioethics Committee of the University of Turin. After the experiment, the carcasses of the treated animals were destroyed in accordance with European Council Directive 2003/74/EC.

Total RNA extraction and quantitative PCR

Total RNA was extracted from the prostate tissue and the BPSCs by the method of Chomczynski and Sacchi (1987) and any residual genomic DNA was removed (DNA-free Kit; Ambion). The integrity of the RNA was confirmed by denaturing agarose gel electrophoresis, and the concentration was measured as the optical density at 260 nm by spectrophotometry. Complementary DNA (cDNA) was synthesised from 400 ng of total RNA using ImProm-II reverse transcriptase (Promega) and random primers (Promega). To determine the amount of the specific target genes (Table 1), cDNA was subjected to quantitative PCR, using the Syber Green method and the IQ 5 (Bio-Rad) detection system. The primer sequences were designed using Primer Express v 1.5 (Applied Biosystems).

The relative amount of gene expression was calculated by a relative quantification assay corresponding to the comparative cycle

threshold (Ct) method. The amount of target, normalised to an endogenous house-keeping gene (glyceraldehyde 3-phosphate dehydrogenase [GAPDH]) and relative to the calibrator (control sample), was then given by $2^{-\Delta\Delta C_t}$ (power), where $\Delta\Delta C_t = \Delta C_t(\text{sample}) - \Delta C_t(\text{control})$, and ΔC_t is the Ct of the target gene subtracted from the Ct of the housekeeping gene.

The data were analysed using GraphPad InStat version 3.00 for Windows (GraphPad Software). The Mann-Whitney U test (a two-sample non-parametric test) was applied to compare the data from the treated and control samples. Differences between data were considered significant at $P < 0.05$.

Cytological and histological investigations

BPSCs were fixed in 100 per cent acetone for 10 minutes at room temperature. Samples of prostate tissue were fixed in 10 per cent neutral buffered formalin overnight at room temperature, embedded in paraffin by routine procedures, and representative sections of each sample were stained with haematoxylin and eosin. To evaluate the expression of the stromal cell markers, immunocytochemistry was applied to the BPSCs, using the following antibodies: anti-smooth muscle actin (clone 1A4; Sigma), anti-desmin (clone DE-U-10; Sigma), anti-smooth myosin (clone HCMV; Sigma) and anti-vimentin (clone AS02; Sigma).

Immunohistochemistry for anti-PR and anti-proliferating cell nuclear antigen (PCNA) was performed on sections of prostate tissue after inactivation of the endogenous peroxidase and antigen retrieval in 0.01M citrate buffer, pH 6.0 for 15 minutes at 700 W. The sections were subsequently incubated with anti-PR clone HPRA2 and HPRA3 (Sigma) and anti-PCNA (Dako) primary antibodies for one hour at room temperature. The immunostaining was visualised with the EnVision kit (Dako) containing secondary antibody labelled with horseradish peroxidase.

Results

Maintenance and characterisation of BPSCs

After seven days in the stromal cell-selective medium, cells began to emerge from the tissue pieces (Fig 1a) and after two to three passages a homogeneous stromal cell culture was obtained (Fig 1b). The cells expressed the following mesenchymal markers: α -actin, desmin, vimentin and smooth muscle myosin (Fig 1c, d, e, f). The residual cells of epithelial origin disappeared after two to three passages, as revealed by negative cytokeratin staining.

Gene expression in BPSCs

The BPSCs challenged with E showed a significant gene over-expression for the FGFRs (power of 1.88 for FGFR1, 3.45 for FGFR2 and 8.41 for FGFR3) (Fig 2). The PR gene was also over-expressed up to 30-fold compared with controls (Fig 2). The gene over-expression was maintained in group S, suggesting that the biological effect persisted for 48 hours after treatment with E_2 had been suspended. The mRNA encoding for ER α was significantly down-regulated (3.45-fold) in the presence of E_2 and a non-significant decrease of transcript corresponding to bFGF was also observed.

The prostate tissue of the veal calves treated with E showed a significant 1078-fold up-regulation of the PR gene and 134-fold up-regulation ($P < 0.05$) of the ER α gene (Fig 3).

Morphological and histological investigations

There were no statistically significant differences between the growth rates of the experimental groups. No muscular lesions were detected at the sites of injection of the drug or placebo, and there were no macroscopic changes in the prostate glands of the treated animals; however, there were severe morphological changes in the form of hyperplasia and metaplasia of the urothelium and glandular epithelium, fibrosis and duct dilation (Fig 4b, d, f, h).

Immunohistochemistry

The epithelial proliferating cells of the treated animals, both in the gland and urethra, were strongly positive to PCNA antigen (Fig 2b, d) compared with the control animals (Fig 2a, c). The over-expression of PR in the prostate gland and urothelium of the treated animals was confirmed by immunohistochemical staining (Fig 2e, f, g, h). There was positive expression in both the nucleus and cytoplasm, suggesting the presence of the nuclear (A) and cytoplasmic (C) isoforms.

Discussion

Oestrogens are the most frequently used illegal growth promoters in animal production. The aim of this study was to identify the genes regulated by oestrogens in the prostate gland, in order to identify a new molecular target to apply in veterinary inspection. By using a quantitative PCR assay, Toffolatti and others (2006) identified seven genes that are differentially expressed in the prostate gland of calves treated experimentally with two combinations of growth promoters (boldenone undecylenate and oestradiol benzoate, and testosterone enanthate and oestradiol benzoate), suggesting further gene targets to apply as biomarkers in veterinary inspection.

In this study, the effects mediated by E_2 in bovine prostate tissues and in primary BPSCs were evaluated. As already described in mouse models (Gail and others 2001), the prostate and urethra of calves treated with oestrogens showed typical histological changes of epithelial metaplasia and hyperplasia (Groot and others 1998). Moreover, the epithelial proliferating cells of the prostate and urethra of the treated animals were strongly positive for PCNA antigen, one of the most important markers involved in mitogenic signals.

Because stromal cells express ER α and have a principal role in the regulation of prostate growth and function in human beings and mice (Cunha and others 2001, 2004b), BPSCs were established and characterised and the biological effects mediated by E_2 on gene expression in them were evaluated. Morphologically, the BPSCs were similar to those described in human beings and reacted to E_2 by modifying the expression of genes encoding for FGFRs and FGFs as already observed in human beings and mice (Kwabi-Addo and others 2004, Graham and Clarke 1997). The treatment of the BPSCs with E_2 induced a two- to three-fold increase in FGFR1, FGFR2 and FGFR3 genes, and this high level of expression remained unchanged for at least 48 hours after the suspension of the treatment with E_2 . In addition, they expressed a 30-fold increase in the gene encoding for PR and this value remained unchanged for 48 hours after the withdrawal of E_2 . The results are similar to those obtained in studies of the mouse prostate, in which E $_2$ induces a significant over-expression of PR protein and mRNA (Gail and others 2001). Moreover, in the BPSCs, there was only a small decrease in the transcripts corresponding to bFGF, androgen receptor, ER α , vascular endothelial growth factor, transforming growth factor β and insulin-like growth factor. It is known that oestrogens induce a down-regulation of the androgen receptor which is mediated by PR isotype A, but the decrease in mRNA encoding for ER α is not completely understood. In human beings, Smith and others (2002)

assume that, in vitro, a high concentration of E₂ saturates the ER α receptor, inducing a decline in its rate of synthesis.

The gene expression profile observed in the BPSCs was also investigated in the prostate glands of veal calves treated with E₂. It was found that 15 days after the last hormone administration, the prostate gland tissue expressed 10⁸- and 1-34-fold increases in the genes encoding for PR and ER α , respectively, but the level of gene expression of the FGF system was unchanged. The involvement of the FGF system in hormone regulation has also been demonstrated in follicle maturation and in the mammary gland in veal calves (Schams and others 2003, Sinowatz and others 2006).

The differences between the expression of the FGF system genes in vitro and in vivo may be related to the experimental models adopted in this study: BPSCs are a homogeneous cell type, whereas the prostate gland contains different cell types, for example, stromal cells and epithelial cells, which respond differently to E₂ treatment. On the other hand, the prostate tissue was examined 15 days after the last treatment, whereas the BPSCs were analysed 48 hours after the withdrawal of E_r. The up-regulation of the FGF-system may not persist for as long as 15 days after the treatment has been discontinued. The results of this study demonstrate that PR isoform A is the most important gene regulated by oestrogen, both in the prostate gland and in BPSCs.

As in human beings, the bovine PR is composed of three distinct isoforms, A, B and C. Isoforms A and B are localised in the nucleus and isoform C is localised in the cytoplasm (Schams and others 2003, Taylor and others 2006). Using specific primers focused on a gene encoding for isoform A, it was shown that E₂ regulated the expression of isoform A, and isoform B was not involved. These data are in agreement with the results of studies in human beings in which it has been shown that the PR isotype A is regulated by oestrogens and acts as a potent activator of progesterone-responsive genes and as a strong trans-dominant repressor of PR isotype B, androgen receptor, mineralocorticoid receptor and ER transcriptional activity (Taylor and others 2006).

In cattle, the regulation of PR isotype A by oestrogens has previously been studied only in the female reproductive system (Van den Broeck and others 2002, D'Haeseleer and others 2007). In the present study, the high level of mRNA encoding for PR was confirmed by protein expression and its detection by immunohistochemistry in prostate tissue. Both the nucleus and the cytoplasm of urethral and epithelial prostate cells were positive. The positive cytoplasm suggests the presence of PR isoform C, already described in human amnion and bovine mammary gland.

This report demonstrates that oestrogens induce an over-expression of PR isotype A in the prostate of prepubertal male calves, and that it is hardly detectable in control calves. These results, and the absence of scientific data on the effects on the expression of PR in bovine prostate tissue of other physiological and pathological conditions, suggest that it might be used as a specific oestrogen-related biomarker to detect the illegal use of oestrogen as a growth promoter in livestock production, specifically in male prepubertal veal calves. These preliminary results suggest that the study of gene expression profiling could lead to the development of specific tests for the detection of the illegal treatment of cattle with anabolic steroids, and support the results of chemical analyses and histopathology. Gene over-expression after the administration of E₂ can be detected for up to 15 days after the treatment is discontinued, whereas chemical methods can detect residues for only a few hours.

Acknowledgements

This project was sponsored by the Regione Piemonte and COOP Italia, Italy. The authors would like to thank Domenico Palmerini, Francesca Spada and Chiara Mulasso for the technical support provided, and the Reference Centre of Comparative Pathology 'Bruno Maria Zaini' of the Faculty of Veterinary Medicine, University of Turin, Italy.

References








- ANON (2006) EU Council Directive 96/22/CE. *Official Journal of the European Community* **L125**, 3,10 BEKTIC, J., OLIVER, A. W., DOBLER, G., KOFLER, K., UEBERALL, F., CULIG, Z., BARTSCH, G. & KLOCKER, H. (2004) Identification of genes involved in estrogenic action in the human prostate using microarray analysis. *Genomics* **83**, 34-44 BIOLATTI, B., CABASSI, E., ROSMINI, R., GROOT, M. J., CASTAGNARO, M., BENEVELLI, R. & OTHERS (2003) Lo screening istologico nella prevenzione dell'uso di anabolizzanti nel bovino. *Large Animal Review* **9**, 9-19 CHOMCZYNSKI, P. & SACCHI, N. (1987) A single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Analytical Biochemistry* **72**, 248-254 EU COUNCIL DIRECTIVE 96/22/CE (1996) *Official Journal of the European Community* L125-10. pp xx-xx EU COUNCIL DIRECTIVE 96/22/CE (1996) *Official Journal of the European Community* L125-3. pp xx-xx COURTHEYN, D., LE BIZEC, B., BRAMBILLA, G., DE BRADANDER, H. F., COBBAERT, E., VAN DE WIELE, M. J. & DE WASCH, K. (2002) Recent developments in the use and abuse of growth promoters. *Analytica Chimica Acta* **473**, 71-82 CUNHA, G. R., CHUNG, L. W. K., SHANNON, J. M. & REESE, B. A. (1980) Stromal-epithelial interactions in sex differentiation. *Biology of Reproduction* **22**, 19-42 CUNHA, G. R., COOKE, P. S. & KURITA, T. (2004a) Role of stromal-epithelial interactions in hormonal responses. *Archives of Histology and Cytology* **67**, 417-434 CUNHA, G. R., RICKE, W., THOMSON, A., MARKER, P. C., RISBRIDGER, G., HAYWARD, S. W., WANG, Y. Z., DONJACOUR, A. A. & KURITA, T. (2004b) Hormonal, cellular and molecular regulation of normal and neoplastic prostatic development. *Journal of Steroid Biochemistry and Molecular Biology* **92**, 221-236 CUNHA, G. R., WANG, Y. Z., HAYWARD, S. W. & RISBRIDGER, G. P. (2001) Estrogenic effects on prostatic differentiation and carcinogenesis. *Reproduction Fertility and Development* **13**, 285-296 D'HAESELEER, M., SIMOENS, P. & VAN DEN BROECK, W. (2007) Cell-specific localization of progesterone receptors in the bovine ovary at different stages of the oestrus cycle. *Animal Reproduction Science* **98**, 271-281 FRANKS, L. M., RIDDLE, P. N., CARBONELL, A. W. & GEY, G. O. (1970) A comparative study of the ultrastructure and lack of growth capacity of adult human prostate epithelium mechanically separated from its stroma. *Journal of Pathology* **100**, 113-119 GAIL, P., RISBRIDGER, G. P., WANG, H., FRYDENBERG, M. & CUNHA, G. (2001) The metaplastic effects of oestrogen on mouse prostate epithelium: proliferation of cells with basal cell phenotype. *Endocrinology* **142**, 2443-2450 GOWARDHAN, B., DOUGLAS, D. A., MATHERS, M. E., MCKIE, A. B., MCCracken, S. R. C., ROBSON, C. N. & LEUNG, H. Y. (2005) Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. *British Journal of Cancer* **92**, 320-327 GRAHAM, J. D. & CLARKE, C. L. (1997) Physiological action of progesterone in target tissue. *Endocrine Reviews* **18**, 502-519 GROOT, M. J., OSSENKOPPELE, J. S., BARKER, R., PFAFFL, M. W., MEYER, H. H. & NIELEN, M. W. (2007) Reference histology of veal calf genital endocrine tissues: an update for screening on hormonal growth promoters. *Journal of Veterinary Medicine A* **54**, 238-246 GROOT, M. J., SHILT, R., OSSENKOPPELE, J. S., BERENDE, P. L. M. & HAASNOOT, W. (1998) Combinations of growth promoters in veal calves: consequences for screening and confirmation methods. *Journal of Veterinary Medicine A* **45**, 425-440 INTERNATIONAL PROSTATE HEALTH COUNCIL (2000) Estrogens and prostatic disease. *Prostate* **45**, 87-100 KROES, R., BERKVEN, J. M., LOENDERSLOOT, H. J. & RUITENBERG, E. J. (1971) Oestrogen-induced changes in the genital tract of male calf. *Zentralblatt für Veterinarmedizin A* **18**, 717-730 KUIPER, G. G., ENMARK, E., PELTO-HUIKKO, M., NILSSON, S. & GUSTAFSSON, J. A. (1996) Cloning of a novel receptor expressed in rat prostate and ovary. *Proceedings of the National Academy of Sciences of the USA* **93**, 5925-5930 KURITA, T., KI-JUN, L., COOKE, P. S., TAYLOR, J. A. & DENNIS, B. (2000) Paracrine regulation of epithelial progesterone receptor by estradiol in the mouse female reproductive tract. *Biology of Reproduction* **62**, 821-830 KWABI-ADDO, B., OZEN, M. & ITTMANN, M. (2004) The role of fibroblast growth factors and their receptors in prostate cancer. *Endocrine Related Cancer* **11**, 709-724 LEAV, I., LAU, K. M., ADAMS, J. Y.,

- MCNEAL, J. E., TAPLIN, M. E., WANG, J., SINGH, H. & HO, S. M. (2001) Comparative studies of the oestrogen receptor beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and primary and metastatic carcinoma. *American Journal of Pathology* **159**, 79-92
- MEYER HEINRICH, H. D. (2001) Biochemistry and physiology of anabolic hormones used for improvement of meat production. *Acta pathologica, microbiologica et immunologica Scandinavica* **109**, 1-8
- NASLUND, M. J. & COFFEY, D. S. (1986) The differential effects of neonatal androgen, oestrogen and progesterone on adult rat prostate growth. *Journal of Urology* **136**, 1136-1140
- RUITENBERG, E. J., KROES, R. & BERKVEN, J. M. (1970) Evaluation of the 'prostate test' in checking the administration of oestrogens in the calf. *Zentralblatt für Veterinärmedizin A* **17**, 351-357
- SCHAMS, D., KOHLENBERG, S., AMSELGRUBER, W., BERISHA, B., PFAFFL, M. W. & SINOWATZ, F. (2003) Expression and localisation of oestrogen and progesterone receptors in the bovine mammary gland during development, function and involution. *Journal of Endocrinology* **177**, 305-317
- SINOWATZ, F., SCHAMS, D., HABERMANN, R., BERISHA, B. & VERMEHREN, M. (2006) Localization of fibroblast growth factor I (acid fibroblast growth factor) and its mRNA in the bovine mammary gland during mammatogenesis, lactation and involution. *Anatomia Histologia Embryologia* **35**, 202-207
- SMITH, P., RHODES, N. P., KE, Y. & FOSTER, C. S. (2002) Upregulation of estrogen and androgen receptors modulate expression of FGF-2 and FGF-7 in human, cultured, prostatic stromal cells exposed to high concentration of estradiol. *Prostate Cancer and Prostatic Disease* **5**, 105-110
- STEINER, M. S. (1993) Role of peptide growth factors in the prostate: a review. *Urology* **42**, 99-110
- TAYLOR, A. H., MCPARLAND, P. C., TAYLOR, D. J. & BELL, S. C. (2006) The progesterone receptor in human term amniochorion and placenta is isoform C. *Endocrinology* **174**, 667-693
- TOFFOLATTI, L., GASTALDO, R. L., PATARNELLO, T., ROMUALDI, C., MER-LANTI, R., MONTESISSA, C., POPPI, L., CASTAGNARO, M. & BARGELLONI, L. (2006) Expression analysis of androgen-responsive genes in the prostate of veal calves treated with anabolic hormones. *Domestic Animal Endocrinology* **30**, 38-55
- VAN DEN BROECK, W., D'HAESELEER, M., CORYN, M. & SIMOENS, P. (2002) Cell-specific distribution of progesterone receptors in the bovine ovary. *Animal Reproduction Science* **37**, 314-320
- VANDERWAL, P., BERENDE, L. M. & SPRIETSMA, J. E. (1975) Effects of anabolic agents of performance on calves. *Journal of Animal Science* **41**, 978-985
- WILLIAMS, K., SAUNDERS, P. T., ATANASSOVA, N., FISHER, J. S., TURNER, K. J., MILLAR, M. R., MCKINNELL, C. & SHARPE, R. M. (2000) Induction of progesterone receptor immunoreactivity in stromal tissue throughout the male reproductive tract after neonatal oestrogen treatment of rats. *Molecular and Cellular Endocrinology* **164**, 117-131
- WONG, Y. C. & TAM, N. N. C. (2002) Dedifferentiation of stromal smooth muscle as a factor in prostate carcinogenesis. *Differentiation* **70**, 633-645
- ZHANG, J., HESS, M. W., THURNHER, M., HOBISCH, A., RADMAYR, C., CRON-AUER, M. V., HITTMAYER, A., CULIG, Z., BARTSCH, G. & KLOCKER, H. (1997) Human prostatic smooth muscle cells in culture: estradiol enhances expression of smooth muscle cell-specific markers. *Prostate* **30**, 117-129

TABLE 1: Target genes selected in quantitative real-time PCR

GenBank accession number	Name	Forward primer	Reverse primer
NM 001001443.1	ER	ACCAACCAGTGCACGATTGA	TTCCGTATCCGCCTTTCAT
AY862875.1	AR	TCCACATTGTCCCTGCTGG	TGAAGAAGTTGCATGGTGCC
XM 583951.3	PR	CCAGAGCCACAGTACAGCTT	CAGCTTCCAC AGGTGAGGACA
AJ004952.1	FGFR1	CGAGACATCCACCACATCGA	TGGGTGTAGATCCGGTCAAAC
Z68150.1	FGFR2	TCCTACGACATCAACCGCG	TGGGAAGCCAAGTACTCCATG
NM 174318.2	FGFR3	AAGATGACGCCACGGATAAGG	GGCGCCTAGCAGTTGATAAT
X54980.1	IGFR	GAGGGAGGTCATGCAGATCG	TCTCGAGCTTCCGGGTC
NM 174056.2	bFGF	GGCTTCTCCTGCGCATC	ACCCCTCTCTTCTGCTTGAA
NM 174621.2	TGF	TGGGCTTTGCTTTGTTTCTGT	CAAATGGCCTGTCTCGTGG
NM 174216.1	VEGF	AGAAAATCCCTGTGGGCCTT	TGCAACGCGAGTCTGTGTTT
U85042.1	GAPDH	ACACCCCAAGATTGTCAGCAA	TCATAAGTCCCTCCACGATGC

AR Androgen receptor, bFGF Basic fibroblast growth factor (FGF), ER Oestrogen receptor, FGFR FGF receptor, GAPDH Glyceraldehyde 3-phosphate dehydrogenase, IGFR Insulin-like growth factor receptor, PR Progesterone receptor, TGF Transforming growth factor, VEGF Vascular endothelial growth factor






FIG 2: Analysis of gene expression under different growth conditions in bovine primary stromal cells (BPSCs) treated with 17β-oestradiol (E₂) (group T), in BPSCs treated with E₂ in which the treatment was suspended for 48 hours (group S) and in control BPSCs (group C). * P<0.05, ** P<0.01. AR Androgen receptor, bFGF Basic fibroblast growth factor (FGF), ER Oestrogen receptor, FGFR FGF receptor, IGFR Insulin-like growth factor receptor, PR Progesterone receptor, TGF Transforming growth factor, VEGF Vascular endothelial growth factor




FIG 3: Analysis of gene expression in prostate tissue from calves treated with 17p-oestradiol (group T) or untreated control calves (group C). *P<0.05. AR Androgen receptor, bFGF Basic fibroblast growth factor (FGF), ER Oestrogen receptor, FGFR FGF receptor, IGFR Insulin-like growth factor receptor, PR Progesterone receptor, TGF Transforming growth factor, VEGF Vascular endothelial growth factor

